🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neovascular Age-Related Macular Degeneration

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration NCT07630649Phase 212 sites📍 Phoenix📍 Bakersfield📍 Fullerton Adverum Biotechnologies, Inc. · Tests: Ixo-vec Extension Study for the Port Delivery System With Ranibizumab (Portal) NCT03683251Phase 3165 sites📍 Phoenix📍 Phoenix📍 Phoenix Hoffmann-La Roche · Tests: PDS Implant with Ranibizumab 100 mg/mL Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT06141460Phase 1, Phase 21 site📍 Tianjin Shanghai Refreshgene Technology Co., Ltd. · Tests: RRG001 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) NCT07547228Phase 1, Phase 21 site📍 Singapore Intra-IMMUSG Pte Ltd · Tests: PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride) OCT Angiography in Wet AMD NCT02253030n/a1 site📍 Portland Oregon Health and Science University · Tests: Optical Coherence Tomography Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT05672121Phase 1, Phase 21 site📍 Beijing Chengdu Origen Biotechnology Co., Ltd. · Tests: KH631 Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting NCT07249216NA1 site📍 Singapore Singapore National Eye Centre · Tests: Faricimab, Ranibizumab Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy NCT07695207Phase 31 site📍 Seoul SANGMYUNG innovation · Tests: SMZ1, SMZ1 Placebo EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD). NCT07434713n/a1 site📍 Bern Insel Gruppe AG, University Hospital Bern · Tests: treatment with Aflibercept 8mg (Eylea) Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration NCT07367282Phase 45 sites📍 Seongnam📍 Seoul📍 Seoul Junyeop Lee · Tests: Faricimab Injection [Vabysmo] Aflibercept in Recurrent or Persistent CNV NCT02669953n/a1 site📍 Vienna Medical University of Vienna · Tests: Aflibercept Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context NCT03577041n/a1 site📍 Amiens Centre Hospitalier Universitaire, Amiens Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD) NCT05803785Phase 12 sites📍 Sydney📍 Sydney Benobio Co., Ltd. · Tests: BBC1501 Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study NCT07516132Phase 38 sites📍 Bakersfield📍 Santa Barbara📍 Waterford Ocular Therapeutix, Inc. · Tests: OTX-TKI Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) NCT07482176Phase 379 sites📍 Mesa📍 Phoenix📍 Phoenix Adverum Biotechnologies, Inc. · Tests: Ixo-vec, Aflibercept Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages NCT07427160n/a1 site📍 Trento Marco Mazzola A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD NCT06346600n/a10 sites📍 Boston📍 Katy📍 Norfolk Skyline Therapeutics · Tests: SKG0106 Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection NCT07446582n/a1 site📍 Woodbridge AI-Spectral · Tests: Retina imaging device (MSI-120) and AI (DeepMSI AI) Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration NCT06742307Phase 41 site📍 Hong Kong Hospital Authority, Hong Kong · Tests: Faricimab Injection [Vabysmo] A Study to Compare GNR-139 and Eylea® in Patients With nAMD NCT07844148Phase 314 sites📍 Cheboksary📍 Chelyabinsk📍 Yekaterinburg AO GENERIUM · Tests: aflibercept, Eylea A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration NCT07614776Phase 381 sites📍 Fullerton📍 Long Beach📍 Modesto Amgen · Tests: ABP 938 8 mg, Aflibercept (US) 8 mg CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) NCT06031727EARLY Phase 12 sites📍 Shanghai📍 Tianjin HuidaGene Therapeutics Co., Ltd. · Tests: HG202 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD NCT06847542Phase 361 sites📍 Innsbruck📍 Linz📍 Mistelbach Hoffmann-La Roche · Tests: Susvimo PDS Implant, Ranibizumab 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration NCT05197270Phase 1, Phase 226 sites📍 Phoenix📍 Oxnard📍 Sacramento 4D Molecular Therapeutics · Tests: 4D-150 IVT, Aflibercept IVT A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO NCT07205887Phase 255 sites📍 Scottsdale📍 Scottsdale📍 Glendale EyeBiotech Ltd. · Tests: Remigromig, Aflibercept 2.0 mg DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information. NCT07308639n/a1 site📍 Leverkusen Bayer · Tests: anti-VEGF medication Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT07064759Phase 3126 sites📍 Scottsdale📍 Sun City📍 Tucson 4D Molecular Therapeutics · Tests: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). NCT04663750Phase 342 sites📍 Bonn📍 Hamburg📍 Ludwigshafen King's College Hospital NHS Trust · Tests: Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, t… Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients NCT07053358EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: LX111 Injection Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) NCT06458595Phase 1, Phase 21 site📍 Tianjin Chengdu Origen Biotechnology Co., Ltd. · Tests: KH658
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy